230 related articles for article (PubMed ID: 28637419)
1. Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents.
Lucas S; Soave C; Nabil G; Ahmed ZSO; Chen G; El-Banna HA; Dou QP; Wang J
Recent Pat Anticancer Drug Discov; 2017; 12(3):190-207. PubMed ID: 28637419
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
Dolušić E; Frédérick R
Expert Opin Ther Pat; 2013 Oct; 23(10):1367-81. PubMed ID: 23992582
[TBL] [Abstract][Full Text] [Related]
4. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
6. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
[TBL] [Abstract][Full Text] [Related]
7. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
[TBL] [Abstract][Full Text] [Related]
9. Advances in NAD-Lowering Agents for Cancer Treatment.
Ghanem MS; Monacelli F; Nencioni A
Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
[TBL] [Abstract][Full Text] [Related]
10. NAD
Kennedy BE; Sharif T; Martell E; Dai C; Kim Y; Lee PW; Gujar SA
Pharmacol Res; 2016 Dec; 114():274-283. PubMed ID: 27816507
[TBL] [Abstract][Full Text] [Related]
11. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals.
Revollo JR; Grimm AA; Imai S
Curr Opin Gastroenterol; 2007 Mar; 23(2):164-70. PubMed ID: 17268245
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.
Montecucco F; Cea M; Bauer I; Soncini D; Caffa I; Lasigliè D; Nahimana A; Uccelli A; Bruzzone S; Nencioni A
Curr Drug Targets; 2013 Jun; 14(6):637-43. PubMed ID: 23531116
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
Front Immunol; 2021; 12():789473. PubMed ID: 34938297
[No Abstract] [Full Text] [Related]
14. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of NAD
Ghanem MS; Caffa I; Monacelli F; Nencioni A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner.
Takeuchi M; Yamamoto T
Exp Cell Res; 2015 Jul; 335(1):62-7. PubMed ID: 26024774
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Khan JA; Forouhar F; Tao X; Tong L
Expert Opin Ther Targets; 2007 May; 11(5):695-705. PubMed ID: 17465726
[TBL] [Abstract][Full Text] [Related]
18. NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.
Pramono AA; Rather GM; Herman H; Lestari K; Bertino JR
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111066
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.
Penberthy WT
Curr Drug Metab; 2007 Apr; 8(3):245-66. PubMed ID: 17430113
[TBL] [Abstract][Full Text] [Related]
20. Switch of NAD Salvage to
Zhang J; Tao J; Ling Y; Li F; Zhu X; Xu L; Wang M; Zhang S; McCall CE; Liu TF
Front Immunol; 2019; 10():2358. PubMed ID: 31681271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
